Clinical DataCardioDx designed a rigorous scientific plan and a prospective, nationwide, multi-center clinical trial to predict to develop and validate Corus CAD. The PREDICT study attempts to determine whether a gene expression identify be developed to identify obstructive CAD in patients with stable chest pain. The company has collected more than 2,800 patient samples in PREDICT from more than 40 clinical centers in the United States in April 2009 http://levitraoverthecounter.net . Study results and the Corus CAD validation data are expected to be published towards the end of 2009.
About CardioDxCardioDx one cardiovascular genomic diagnostics company is offering doctors clinically validated tests for better informed and individual patient care to make decisions. Coronary artery disease , cardiac arrhythmias and heart failure: We are a strategic focus on the development of products for the three forms of cardiovascular disease. The company’s first product, Corus CAD is the first and only gene expression test to determine the likelihood of obstructive coronary artery disease in a stable chest pain patients quantify. Developed and manufactured in a multicenter U.S. Study confirms in 2010. Activity of a group of genes which assess other patient characteristics obstructive coronary artery disease. Corus CAD nine states nine states – Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona – expected on the CardioDx CLIA-certified commercial laboratory with wider availability in 2010. CardioDx in 2004 in 2004 and is located in Palo Alto, California.
The analytical method they develops will be already been developed for the 1000 Genomes Project, an international effort to catalog and compare the Genome from hundreds of people from across the globe.